Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04001036
Other study ID # IP-001-09
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 1, 2019
Est. completion date August 30, 2022

Study information

Verified date August 2022
Source Iperboreal Pharma Srl
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, randomized, controlled clinical trial. The aim is to compare the effects of the peritoneal dialysis solution IPX15, containing glucose (0.5%), xylitol (1.5%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 2.5% glucose PD solution), for the nocturnal exchange with the PD solution IPX07, containing glucose (0.5%), xylitol (0.7%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 1.5% glucose PD solution), for the diurnal (short dwell) exchanges. Planned total recruitment is 40 patients with stable end-stage renal disease (ESRD) treated by continuous ambulatory peritoneal dialysis (CAPD). Treatment duration will be 4 weeks plus a 4 weeks safety follow up with no treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date August 30, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of ESRD treated for at least three months with CAPD, as stated by the medical staff of the center; - Stable clinical condition within four weeks before the screening period, certified by medical/surgical history, physical examination and laboratory exploration; - Hemoglobin level = 9g/dL; - Absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection; - To understand and sign an informed consent form. Exclusion Criteria: - History of alcohol or drug abuse in the last six months before selection for the study; - Androgen therapy in the last six months before selection; - Active infections; - History of congestive heart failure stage III and IV New York Heart Association (NYHA); - History of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection; - Clinically relevant cardiac arrhythmia; - Clinically relevant abnormalities of functional hepatic tests; - Therapy with L-carnitine or its derivatives in the last three months before selection; - Pregnancy, lactating women or female subjects of childbearing potential who do not use an effective method of contraception; - Presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with the assessment of study parameters, especially if the life expectancy is less then one year; - Participation in another clinical study within the past month; - Known allergic reactions to L-carnitine or xylitol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
One bag for nocturnal (long-dwell) exchange.
0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
One to three, daily (short-dwell) exchanges

Locations

Country Name City State
Italy Department of Nephrology, University of Chieti Chieti

Sponsors (1)

Lead Sponsor Collaborator
Iperboreal Pharma Srl

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Daily ultrafiltration volume Change from baseline 28 days
Secondary Peritoneal equilibration test Change from baseline 28 days
Secondary Weekly total urea Kt/V Change from baseline 28 days
Secondary Weekly total creatinine clearance Change from baseline 28 days
Secondary Adverse Events Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected, recorded and followed as appropriate. 2 months
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A